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At the invitation of the Nordrhein Westfalen authorities, the Robert Koch-Institut in Berlin has assisted 
with interviewing 1200 people and determining the vaccination status at a school in Duisburg where 
there were 37 patients. Current studies aim to determine the contribution of areas of low coverage to 
the outbreak and vaccination records are being studied. All patients whose records show that they are 
not protected will receive an information leaflet provided by the Deutsches Grünes Kreuz e.V. (DGK, 
http://www.dgk.de). 
The Nordrhein Westfalen state health authorities are also carrying out a telephone survey of all known 
patients in Duisburg. This survey will provide data needed to compile comprehensive information on 
the extent of the outbreak, illness length, possible infection sources and transmission routes. 
This article was translated and adapted from reference 1 by the Eurosurveillance editorial team. 
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Since March 2005, 255 000 cases of chikungunya fever are estimated to have occurred on the island of 
Réunion, a French overseas department in the Indian Ocean [1]. An huge increase in estimated cases 
occurred at the end of December 2005, culminating in an estimated peak incidence of more than 40 
000 cases in week 5 of 2006 [2]. Since then, the estimated weekly incidence trend is downwards, 
although there have been an estimated 3000 new cases per week since week 13 of 2006. In total, 213 
deaths have been linked to the disease [1]. In Mayotte, the nearby French territorial collectivity, 5834 
cases have been notified [3]. Chikungunya cases have also been reported on other islands in the 
Indian Ocean, and imported cases have been confirmed in several European countries (Table). 
Table. Number of chikungunya cases reported by various countries, February 2005 to April 2006*.  
Country
No. of 
cases
Suspected (S) or 
confirmed (C)
Reporting period
Indian Ocean and Asia
Réunion 255 000 S 
28 Feb 05 – 30 Apr 
06
Mayotte 5834 S 
1 Jan 06 – 16 Apr 
06
Seychelles 8818 S 
1 Jan 06 - 26 Feb 
06
Seychelles 158 S 
29 Mar 06 – 2 Apr 
06
Comoros 8 C 20 – 26 Mar 06 
Madagascar 2 C 6 – 12 Mar 06
Mauritius 6000 4800 S + 1200 C 
1 Jan 06 – 5 Mar 
06
India > 100 000 S Dec 05 - 23 Apr 06
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*The data in this table is not meant to be exhaustive, and is based on information supplied by 
Eurosurveillance editorial advisors and the Institut de Veille Sanitaire in April and May 2006.** 
In light of the extent of the epidemic and the extensive travel between affected areas and Europe 
throughout the year, the short term risk of introduction and transmission of Chikungunya virus in 
Europe was assessed by a multidisciplinary European expert panel that met at the end of March 2006 
at the European Centre for Disease Prevention and Control (ECDC).  
Two main elements were identified for the risk assessment for Europe. Firstly, the virus, which appears 
to be a variant of previously characterised strains, is currently being imported into Europe by infected 
people travelling from high incidence areas in the Indian Ocean to Europe*. A large proportion of these 
travellers have family ties to the area and travel there to visit friends and relatives, and may not 
realise the importance of taking preventive measures to reduce the risk of Chikungunya virus infection 
during their stay abroad. France and several other European countries have confirmed Chikungunya 
virus infections in tourists returning from the Indian Ocean. The likelihood of virus introduction through 
the importation of infected vectors, or contamination through breach of universal precautions when 
handling blood samples or through blood transfusions, was considered to be relatively low, although 
more research is needed. However, there has already been a laboratory confirmed case in a nurse in 
France who became infected after taking a blood sample from an acutely ill chikungunya patient.  
Secondly, the Aedes albopictus mosquito that has been the epidemic vector in Réunion has already 
been introduced into several European countries, including Belgium, Bosnia and Herzegovina, Croatia, 
France, Greece, the Netherlands, Serbia and Montenegro, Slovenia, Spain and Switzerland. Importation 
is thought to have occurred through the trade of used tyres (the mosquito lays eggs in pools of water 
in the tyres) and ornamental plants which are transported in water, notably species of Dracaena trees 
and shrubs (including ‘lucky bamboo’). This has resulted in the establishment of this mosquito in 
Albania, Northern/Central Italy, and limited foci in other countries [4,5,6]. Most of southern Europe has 
potentially favourable climate and ecological conditions for local establishment of A. albopictus. 
However, the vectorial competence and capacity of A. albopictus for transmission of Chikungunya virus 
in infested areas is not yet known, and research is currently being carried out in France. Based on 
current knowledge, it is considered highly likely that this mosquito species is able to transmit the virus 
within Europe, but the efficiency of virus transmission is not yet known. 
Conclusion 
There is a risk of Chikungunya virus transmission in Europe, but although the magnitude of this risk 
cannot be precisely determined at this time, it is thought that any risk is likely to be limited to small 
areas within certain countries. 
There is a risk of Chikungunya virus importation from other parts of the world, including Africa, India, 
and South East Asia, where the virus is endemic. More than 100 000 chikungunya cases have been 
reported in India since December 2005. With the risk of importation of other vector-borne viruses into 
Europe such as the dengue virus for example [7] (which can also be transmitted by the A. albopictus 
mosquito), the recommendations presented below could be used as the basis for broadening the scope 
of the discussions, to ensure that measures to prevent the emergence of imported viral diseases are 
strengthened in Europe.  
Malaysia 200 S 
1 Jan 06 - 21 Apr 
06
Europe (imported cases)
France 307 C 
1 Apr 05 – 28 Feb 
06
Germany 17 C 
1 Jan 06 – 21 Apr 
06
United 
Kingdom
9 2 C + 7 S 
1 Dec 05 – 20 Apr 
06
Belgium 12 C 
Dec 05 – 26 Apr 
06
Czech 
Republic
1 C 
1 Jan 06 – 20 Apr 
06
Norway 1 C 
1 Jan 06 – 19 Apr 
06
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Recommendations 
In the short term, recommendations include: 
In the longer term, further studies and documentation of vector competence and capacity of A. 
albopictus would be useful in areas in Europe where these vectors are known to be present. Areas at 
risk of vector establishment need to be identified and regularly monitored, and vector surveillance 
implemented or strengthened in these areas. Finally, measures to prevent the introduction of A. 
albopictus through the used tyre trade and plants transported in water (e.g Dracaena species) should 
be considered.  
*Eurostat estimated that in 2004, a total of 1 474 218 people travelled from Madagascar (153 766), 
Mauritius (657 312), Mayotte (63 372) Réunion (498 388) and Seychelles (101 380) to the European 
mainland. 
This report summarises the main conclusions of the meeting of the one-day consultation held at the 
European Centre for Disease Prevention and Control (ECDC) in Stockholm on 30 March 2006, and the 
recommendations that the ECDC Chikungunya risk assessment group has made to EU member states. 
  
**Correction. This note was missing from the article as originally published on 11 May. It was added 
on 15 May 2006.  
Eurosurveillance editorial office, 15 May 2006.  
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Mounting evidence of the efficacy of human papillomavirus vaccines 
Editorial team (eurosurveillance.weekly@hpa.org.uk), Eurosurveillance editorial office 
Since virus-like particles (VLP) generated by the synthesis and self-assembly in vitro of the major 
human papillomavirus (HPV) capsid protein (L1) were shown to work in principle as a vaccine candidate 
[1], Phase II vaccine trials over the past two years have shown good results for safety, 
  
Providing information to all people travelling from the affected areas 
with high disease incidence
  
Providing Chikungunya virus fact sheets to physicians, as returning 
travellers may present with the disease, 
  
Reminding medical staff of the need to follow universally accepted 
precautions when handling samples from all patients, including those 
presenting with chikungunya fever 
  Advising European Union member states on blood donation policies; 
  
Assessing the capability and capacity of laboratories in Europe to 
diagnose chikungunya fever.
Page 5 of 8Eurosurveillance 2006;11 (5): 060511
11-3-2008http://www.eurosurveillance.org/ew/2006/060511.asp
* IN= intraepithelial neoplasia 
These trial results suggest that HPV vaccines may soon be available that are well tolerated and can 
protect both against persistent HPV infection and cervical intraepithelial neoplasia and, by implication, 
against cervical cancer. Marketing applications have been submitted for review to European and United 
States drug regulatory authorities. Licensure is expected for women only in the first instance. HPV 
vaccination is expected to be most effective at preventing cervical disease when given to girls and 
young women who are uninfected with HPV 16 or 18. Ongoing and further trials are expected to 
produce more data on these vaccines’ safety and immunogenicity in both women and men, at different 
ages, and for individuals who have already been exposed to HPV infection, as well as information on 
the duration of vaccine-induced antibodies and protection from HPV infection and related disease.  
Around 30% of cervical cancers worldwide are associated with 11 other oncogenic HPV types (31, 33, 
35, 39, 45, 51, 52, 56, 58, 59 and 66). Cross-protection from the bivalent vaccine against infection 
with HPV types 31 and 45 with efficacy of 55% (95%CI 12-78) and 94% (95%CI 63-100), 
respectively, has been reported [5]. Increases in titres of type-specific antibodies for HPV types 31, 45, 
52 and 58 following vaccination with the quadrivalent vaccine have been shown [8]. However, efficacy 
of the quadrivalent vaccine against infection with any non-vaccine HPV type, and efficacy of either 
vaccine against disease associated with non-vaccine HPV types has not yet been reported. Evidence of 
efficacy against other cancers (e.g. some ano-genital and head and neck cancers) associated with HPV 
16 and 18 may also be relevant to the expected impact and cost-effectiveness of HPV vaccination.  
In many European countries, cervical screening and the resulting treatment of cervical disease 
detected at early stages have been very successful at reducing the incidence and mortality of cervical 
cancer. If prophylactic HPV vaccines are introduced, cervical screening is expected to remain important 
for non-immunised women, for older (previously infected) women and for the detection of disease 
associated with non-vaccine HPV types.  
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- Intention to 
treat
100% (42-100) [0:8] 100% (56-100) [0:10]
Geometric mean 
antibody titre at 
last reported 
follow-up 
compared to that 
of natural 
infection (per 
protocol)
Month 51-53 Month 36
HPV16: 17-fold HPV16:18-fold
HPV18: 14-fold HPV18: 2-fold
Patients reporting 
serious adverse 
events
22(4%):19 (3.5%)
(months 0-27)
2(1%):2(1%) (months 0-
36)
16 (4%):19 (5%)(months 
27-53) None related to 
vaccination.None related to 
vaccination.
Injection site 
adverse events
499(94%):472(88%) 234(86%):212 (77%)
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